Gardasil is a new vaccine developed by Merck for the prevention of cervical cancer. HPV is the most common cause of cervical cancer in women.
Home About Us Information Press Releases


Welcome to iGardasil.com

This Gardasil website is not affiliated with Merck, but rather a informative collection of Gardasil related information. We have taken the libert of gathering information on the Gardasil vaccine. In clinical studies Gardasil has proven to greatly reduce the risk of contracting specific types of HPV, which are known to cause cervical cancer.

"The level of protection in this study against infection with these four HPV types (sic HPV 6, 11, 16, and 18), including pre-cancerous lesions, was significant," said the study's lead investigator, Luisa Villa, PhD, head of the Virology Group at the Ludwig Institute for Cancer Research, São Paulo branch.

In the study, 552 women in the United States, Europe and Brazil between the ages of 16 and 23 were randomized to receive vaccine or placebo at Day 1, Month 2, and Month 6. The primary endpoint of the study was to assess the efficacy of the investigational vaccine in reducing the combined incidence of persistent HPV 6, 11, 16, and 18 infections and related diseases, including cervical pre-cancers (cervical intraepithelial neoplasia, or CIN), cervical cancer, and/or external genital lesions (genital warts). referenced from- http://www.medicalnewstoday.com/medicalnews.php?newsid=22445.

On June 8th, Gardasil, a vaccine against the virus that causes most cervical cancers, most cancers of the vagina and vulva, and genital warts, won FDA approval today.

"Gardasil is a major health breakthrough -- the first vaccine specifically designed to prevent cancer -- and is approved to prevent not only cervical cancer but also genital warts," says Kevin Ault, MD, leader of Gardasil clinical trials at Atlanta's Emory University, in a Merck news release.

Top Gardasil Information Websites:

Medical News Today
Merck Gardasil Site
WebMD
FDA
About.com

More articles and Press Releases: